T. Rowe Price Associates, Inc. 13D and 13G filings for Vertex Pharmaceuticals Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 2:34 pm Sale | 2021-12-31 | 13G | Vertex Pharmaceuticals Incorporated VRTX | T. Rowe Price Associates, Inc. | 5,421,291 2.100% | -14,204,917 (-72.38%) | Filing |
| 2021-02-16 12:23 pm Sale | 2020-12-31 | 13G | Vertex Pharmaceuticals Incorporated VRTX | T. Rowe Price Associates, Inc. | 19,626,208 7.500% | -4,899,697 (-19.98%) | Filing |
| 2020-02-14 1:29 pm Sale | 2019-12-31 | 13G | Vertex Pharmaceuticals Incorporated VRTX | T. Rowe Price Associates, Inc. | 24,525,905 9.500% | -1,223,506 (-4.75%) | Filing |